[go: up one dir, main page]

EP1002073A2 - Procede d'activation de cellule et reactifs a cet effet - Google Patents

Procede d'activation de cellule et reactifs a cet effet

Info

Publication number
EP1002073A2
EP1002073A2 EP98930934A EP98930934A EP1002073A2 EP 1002073 A2 EP1002073 A2 EP 1002073A2 EP 98930934 A EP98930934 A EP 98930934A EP 98930934 A EP98930934 A EP 98930934A EP 1002073 A2 EP1002073 A2 EP 1002073A2
Authority
EP
European Patent Office
Prior art keywords
dna
delivery system
components
component
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98930934A
Other languages
German (de)
English (en)
Inventor
Helene Margaret Finney
Alastair David Griffiths Lawson
Andrew Neil Charles Weir
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celltech R&D Ltd
Original Assignee
Celltech Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech Therapeutics Ltd filed Critical Celltech Therapeutics Ltd
Publication of EP1002073A2 publication Critical patent/EP1002073A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Definitions

  • This invention relates to a process for activating cells, a DNA delivery system for achieving cell activation and the use of activated cells in medicine.
  • the natural T-cell receptor is a complex association of polypeptide chains comprising antigen binding, transmembrane and cytoplasmic components. Binding of antigen to the receptor in the correct context triggers a series of intracellular events leading to activation of the T-cell and for example destruction of the antigen presenting target cell. Before recognition of the antigen can take place, the antigen must be presented in association with MHC molecules.
  • Chimeric receptors have been designed to target T-cells to cells expressing antigen on their cell surface.
  • Such recombinant chimeric receptors include chimeras containing binding domains from antibodies and intracellular signalling domains from the T-cell receptor, termed 'T- bodies' [see for example Published International Patent Specifications Nos. WO 92/10591 , WO 92/15322, WO 93/19163 and WO 95/02686].
  • the recombinant chimeric receptors described in the art are composed of a ligand binding component, a transmembrane component and a cytoplasmic component. It has been found however, that transfection of T-cells with these recombinant chimeric receptors does not result in acceptable levels of T-cell activation upon antigen binding unless the T- cell is also co-stimulated by, for example, treatment with high levels of interleukin 2 [11-2]. The need for co-stimulation makes the method suitable principally for ex-vivo treatment of patients. This is a lengthy and complicated procedure.
  • chimeric receptor contains two or more different signalling cytoplasmic components which are not naturally linked and which advantageously are chosen to act together cooperatively to produce improved activation of the cell.
  • DNA coding for such recombinant chimeric receptors may be introduced into T-cells or other effector cells in-vivo and/or ex-vivo.
  • the DNA coding for the chimeric receptor(s) is arranged such that when it is expressed, and on the extracellular interaction between the cell and a second target cell, a signal is transduced via the cytoplasmic signalling components to two or more different intracellular signalling messengers. This results in activation of the cell and elicits a biological response to the target cell.
  • cell activation means activation of one or more signal transduction pathways. This may be evidenced by an increase in cell proliferation; expression of cytokines with, for example pro or anti- inflammatory responses; stimulation of cytolytic activity, differentiation or other effector functions; antibody secretion; phagocytosis; tumour infiltration and/or increased adhesion.
  • the cytoplasmic signalling components are preferably selected such that they are capable of acting together cooperatively. They are "not naturally linked", which term is used herein to denote cytoplasmic signalling components which in nature are not connected to each other on a single polypeptide chain.
  • the cytoplasmic signalling components are those which are capable of linking to and/or generating a response in one or more cytoskeletal components of the cell in which they are expressed.
  • Particularly useful signalling components include those described hereinafter in relation to other aspects of the invention.
  • each recombinant chimeric receptor preferably comprises a binding component capable of recognising a cell surface molecule on a target cell, and a transmembrane component.
  • the DNA coding for these components will additionally code for a signal peptide to ensure that the chimeric receptor(s) once expressed will be directed to the cell surface membrane. All the components may be coded for by a single DNA coding sequence.
  • each cytoplasmic signalling component may be coded for by two or more separate DNA coding sequences.
  • each DNA coding sequence may also code for a signal peptide, a transmembrane component and/or a binding component.
  • the binding components may be different, but will generally all be capable of participating in the same type of extracellular event, for example by binding to the same molecule associated with the target cell. In one preference the binding components are the same.
  • the DNA coding for the chimeric receptor may comprise two separate DNA coding sequences, one sequence for example coding for part of the binding component [in the case of an antibody for example a VH component] linked to the signal peptide, transmembrane and cytoplasmic signalling component(s), and the second sequence coding for the remainder of the binding component [for example a V
  • a DNA delivery system comprising DNA in association with a carrier said DNA coding for a recombinant chimeric receptor capable of one type of extracellular interaction and comprising two or more different cytoplasmic signalling components which are not naturally linked, and wherein at least one of said cytoplasmic components is derived from a membrane spanning polypeptide characterised in that at least one of said cytoplasmic signalling components is a co-stimulatory signalling domain derived from all or part of a tetra-span-transmembrane protein, CD9, CD43, CD6, a mannose, IL- 7, IL-12 or complement receptor, an integrin-associated protein, or a ⁇ - chain associated with a cytokine receptor.
  • the chimeric receptor may be coded for by a single DNA coding sequence, coding in particular for the two or more different cytoplasmic signalling components.
  • the invention provides a DNA delivery system comprising DNA in association with a carrier said DNA coding for a recombinant chimeric receptor wherein said DNA codes in reading frame for:
  • cytoplasmic signalling components i) a signal peptide component; ii) a binding component capable of recognising a cell surface molecule on a target cell; iii) a transmembrane component; iv) two or more different cytoplasmic signalling components which are not naturally linked, and wherein at least one of said cytoplasmic components is derived from a membrane spanning polypeptide, and optionally v) one or more spacer regions linking any two or more of said i) to iv) components, characterised in that at least one of said cytoplasmic signalling components is a co-stimulatory signalling domain derived from all or part of a tetra-span-transmembrane protein, CD43, CD6, a mannose,
  • IL-7 IL-7, IL-12 or complement receptor, an integrin-associated protein or a ⁇ -chain associated with a cytokine receptor.
  • the components of the recombinant chimeric receptor are operatively linked such that the signalling cytoplasmic components are functional in transducing a signal resulting in activation of one or more messenger systems as a result of recognition of a cell surface molecule on a target cell by the binding component.
  • Two or more of the components may be linked by one or more spacer regions.
  • the spacer regions may function to facilitate the components adopting the correct conformation for biological activity.
  • the use of a spacer region to link the transmembrane component iii) and the binding component ii) is particularly advantageous.
  • the spacer regions may for example comprise up to 300 amino acids and preferably 20 to 100 amino acids and most preferably 25 to 50 amino acids.
  • Spacers may be derived from all or part of naturally occurring molecules such as from all or part of the extracellular region of CD8, CD4 or CD28; or all or part of an antibody constant region, including the hinge region. All or part of natural spacing components between functional parts of intracellular signalling molecules for example spacers between ITAMS (immunoreceptor tyrosine based activation motifs) may also be used. Alternatively the spacer may be a non-naturally occurring sequence.
  • the binding component ii) may be any molecule capable of interacting with cell surface molecules and may be chosen to recognise a surface marker expressed on cells associated with a disease state such as for example those associated with virally infected cells; bacterially infected cells; cancer cells, such as the bombesin receptor expressed on lung tumour cells, carcinoembryonic antigen, polymorphic epithelial mucin, and CD33; peptide hormones, adhesion molecules, inflammatory cells present in autoimmune disease, or a T-cell receptor or antigen giving rise to autoimmunity.
  • a disease state such as for example those associated with virally infected cells; bacterially infected cells; cancer cells, such as the bombesin receptor expressed on lung tumour cells, carcinoembryonic antigen, polymorphic epithelial mucin, and CD33; peptide hormones, adhesion molecules, inflammatory cells present in autoimmune disease, or a T-cell receptor or antigen giving rise to autoimmunity.
  • Suitable binding components for use in the chimeric receptors of the invention also include all or part of receptors associated with binding to cell surface associated molecules; the T-cell receptor; CD4; CD8; CD28; cytokine receptors e.g. an interleukin receptor, TNF receptor, or interferon receptor e.g. ⁇ -IFN; receptors for colony stimulating factors e.g. GMCSF; antibodies and antigen binding fragments thereof including for example Fab, Fab', F(ab')2, single chain Fv, Fv, and VH or V
  • the antibodies or fragments may be murine, human, chimeric or engineered human antibodies and fragments.
  • engineered human antibody or fragment is intended to mean an antibody or fragment which has one or more CDR's and one or more framework residues derived from one antibody, e.g. a murine antibody embedded in an otherwise human framework.
  • Such antibodies are well known and may be prepared by a number of methods for example as described in International Patent Specification No. WO91/09967.
  • Particularly useful binding components include Fab' fragments or, especially, single chain Fv fragments.
  • the binding component is an antibody or antibody fragment other than a single chain Fv or VH or V
  • the first DNA sequence containing the cytoplasmic signalling components and one chain of the antibody or fragment will be coexpressed with the second DNA sequence coding for a signal peptide and the second chain of the antibody or fragment so that assembly of the antibody binding component can occur.
  • Transmembrane components iii) may be derived from a wide variety of sources such as all or part of the alpha, beta or zeta chain of the T-cell receptor, CD28, CD8, CD4, a cytokine receptor, e.g. an interleukin receptor, TNF receptor, or interferon receptor, or a colony stimulating factor receptor e.g. GMCSF.
  • sources such as all or part of the alpha, beta or zeta chain of the T-cell receptor, CD28, CD8, CD4, a cytokine receptor, e.g. an interleukin receptor, TNF receptor, or interferon receptor, or a colony stimulating factor receptor e.g. GMCSF.
  • the transmembrane component may be the transmembrane domain associated in nature with the co-stimulatory signalling domain as described herein, and may be derived from a tetra-span-transmembrane protein, CD43, CD6, a mannose, IL-7, IL-12 or complement receptor, an integrin-associated protein or a ⁇ -chain associated with a cytokine receptor.
  • the binding and transmembrane components may be linked directly or, preferably, by a spacer region.
  • the spacer region may be one or more of the regions described above. Where more than one region is present, for example two regions, these are preferably different regions, for example an antibody hinge region linked to all or part of the extracellular region of CD28.
  • the spacer and transmembrane components are advantageously chosen such that they have free thiol groups thereby providing the chimeric receptor with multimerisation, particularly dimerisation capacity.
  • Receptors of this type, especially dimers are particularly preferred and include those which have CD28 components, the zeta chain of the natural T-cell receptor, and/or antibody hinge sequences.
  • the transmembrane component may or may not be naturally linked to the cytoplasmic component to which it is attached either directly or by means of a spacer.
  • the cytoplasmic signalling components iv) can for example transduce a signal which results in activation of one or more intracellular messenger systems. It is preferred that each of the cytoplasmic components activates a different messenger system.
  • the intracellular messenger systems which may be activated either directly or indirectly include, for example, one or more kinase pathways such as those involving tyrosine kinase, PKC or MAP kinase; G-protein or phospholipase mediated pathways; calcium mediated pathways; and pathways involving synthesis of a cytokine such as an interleukin e.g. IL-2, including NFAT, and cAMP mediated pathways.
  • At least one of the cytoplasmic signalling components iv) will be a co- stimulatory signalling domain derived from all or part of the receptors particularly described above.
  • at least the signalling domain, or the signalling and transmembrane domains may be used, together with the remainder of the receptor as desired, for example to make use of any convenient restriction sites when initially constructing the DNA coding for the receptor.
  • the co-stimulatory signalling domain may be derived from all or part of a tetra-span-transmembrane protein for example CD9 [Lanza, F et alJ. Biol. Chem. 266, 10638-10645 (1991 )], especially amino acids from around 36 to around 227; CD37 [Classon, R. et al J.Exp, Med. 172, 1007 (1990)] especially amino acids from around 38 to around 281 , CD53 [Angelisova P. et al Immunogenetics 32, 281 -285 (1990], especially amino acids from around 37 to 219, CD63 [Metzelaar, M . et al J. Biol.
  • Med. 172, 1785-1794 (1990)] especially amino acids from around 1394 to around 1438 or from around 1370 to around 1438; an IL-7 receptor ⁇ chain (CD127) [Goodwin R.G. Cell 60, 941 -951 (1990)], especially amino acids from around 245 to around 439 or from around 220 to around 439; an IL-12 receptor ⁇ -chain [Preskey D. et al P.N.A.S. 93, 14002-14007 (1996)], especially amino acids from around 647 to around 862 or from around 623 to around 862; a complement receptor, e.g. CR1 (CD35) [Wong, W., P.N.A.S.
  • 227 may be used as an alternative to DNA coding for the full length CD9 signalling domain of amino acid residues 36-227. Fragments of other signalling domains may be advantageously used following the same principles, the size of each fragment depending on the nature of the DNA coding for the parent domain and/or the amino acid sequence of the domain, in particular the location of any restriction and/or glycosylation sites. Such sites can be readily identified in a parent sequence by inspection or other conventional means.
  • One useful co-stimulatory signalling domain is that derived from all or part of a tetra-span-transmembrane protein, particularly CD9.
  • cytoplasmic components iv) which may be present in the receptors according to the invention include, for example those derived from the T-cell receptor such as all or part of the zeta, eta or epsilon chain; CD28; the ⁇ chain of a Fc receptor; or signalling components from a cytokine receptor e.g. interleukin, TNF and interferon receptors, a colony stimulating factor receptor e.g. GMCSF, a tyrosine kinase e.g. ZAP-70, fyn, lyk, Itk and syk; an adhesion molecule e.g. LFA-1 and LFA-2, B29, MB-1 , CD3 delta, CD3 gamma, CD5 or CD2.
  • the signalling cytoplasmic components are preferably ITAM containing cytoplasmic components
  • the cytoplasmic signalling components are preferably selected so that they act cooperatively. They may be in any orientation relative to one another. Particularly useful components include all or part of the signalling component of CD28, the zeta chain of theT-cell receptor or the ⁇ chain of
  • Fc ⁇ R1 or Fc ⁇ R11 1 in addition to the co-stimulatory signalling domains described above.
  • the signal component may be that naturally associated with the binding component or may be derived from other sources.
  • Suitable signal peptide components i) include immunoglobulin signal sequences.
  • the signal component, binding component, transmembrane component, and cytoplasmic components are preferably derived from or based on human sequences. Homologues of the individual components of the chimeric receptor may be used and the invention is to be understood to extend to such use.
  • the term homologue as used herein with respect to a particular nucleotide or amino acid sequence coding for a component of the chimeric receptor represents a corresponding sequence in which one or more nucleotides or amino acids have been added, deleted, substituted or otherwise chemically modified provided always that the homologue retains substantially the same function as the particular component of the chimeric receptor. Homologues may be obtained by standard molecular biology and/or chemistry techniques e.g.
  • oligonucleotide directed mutagenesis by cDNA or gene cloning, or by use of oligonucleotide directed mutagenesis or oligonucleotide directed synthesis techniques or enzymatic cleavage or enzymatic filling in of gapped oligonucleotides.
  • Fragments of the individual components may also be used wherein one or more nucleotides has been deleted provided that the fragment retains substantially the same function as the starting component of the chimeric receptor.
  • the DNA for use in this and other aspects of the invention may be obtained from readily available DNA sources using standard molecular biology and/or chemistry procedures, for example by use of oligonucleotide directed mutagenesis or oligonucleotide directed synthesis techniques, enzymatic cleavage or enzymatic filling in of gapped oligonucleotides.
  • oligonucleotide directed mutagenesis or oligonucleotide directed synthesis techniques enzymatic cleavage or enzymatic filling in of gapped oligonucleotides.
  • Such techniques are described by Maniatis et al in Molecular Cloning, Cold Spring Harbor Laboratory, New York 1989, and in particular in the Examples hereinafter.
  • the carrier for use in the DNA delivery systems according to the invention may be a vector or other carrier suitable for introduction of the DNA ex- vivo or in-vivo into target cells and/or target host cells.
  • suitable vectors include viral vectors such as retroviruses, adenoviruses, adenoassociated viruses, EBV, and HSV, and non-viral vectors, such as liposomal vectors and vectors based on DNA condensing agents.
  • the carrier may be an antibody.
  • the vector may additionally include promoter/regulatory sequences and/or replication functions from viruses such as retrovirus LTRs, AAV repeats, SV40 and hCMV promoters and/or enhancers, splicing and polyadenylation signals; EBV and BK virus replication functions.
  • viruses such as retrovirus LTRs, AAV repeats, SV40 and hCMV promoters and/or enhancers, splicing and polyadenylation signals; EBV and BK virus replication functions.
  • Tissue specific regulatory sequences such as the TCR- ⁇ promoter, E-selectin , promoter and the CD2 promoter and locus control region may also be used as can inducible promoters, such as hypoxia-induced promoters.
  • DNA molecules may be incorporated into the same or different carriers as described above.
  • the DNA delivery system of the invention may be introduced into effector cells removed from the target host using methods well known in the art e.g. transfection, transduction, biolistics, protoplast fusion, calcium phosphate precipitated DNA transformation, electroporation, cationic lipofection, or targeted liposomes.
  • the effector cells are then reintroduced into the host using standard techniques.
  • target hosts such as, for example, mammals and, especially, humans.
  • Suitable effector cells include cells associated with the immune system such as lymphocytes e.g. cytotoxic T-lymphocytes, tumour infiltrating lymphocytes, natural killer cells, neutrophils, basophils, eosinophils, mast cells, or T-helper cells; dendritic cells, B-cells, haemoatopaietic stem cells, macrophages, or monocytes.
  • lymphocytes e.g. cytotoxic T-lymphocytes, tumour infiltrating lymphocytes, natural killer cells, neutrophils, basophils, eosinophils, mast cells, or T-helper cells
  • dendritic cells B-cells, haemoatopaietic stem cells
  • macrophages or monocytes.
  • the co-stimulatory signalling domain is preferably derived from all or part of an integrin-associated protein or in particular all or part of a mannose or complement receptor or associated protein.
  • the ⁇ chain of a Fc receptor
  • the DNA delivery system according to the invention is particularly suitable for in vivo administration. It may be in one preferred example in the form of a targeted delivery system in which the carrier is capable of directing the DNA to a desired effector cell. Particular examples of such targeted delivery systems include targeted-naked DNA, targeted liposomes encapsulating and/or complexed with the DNA, targeted retroviral systems and targeted condensed DNA such as protamine and polylysine condensed DNA.
  • Targeting systems include using, for example, antibodies or fragments thereof against cell surface antigens expressed on target cells in vivo such as CD8; CD16; CD4; CD3; selectins e.g. E-selectin; CD5; CD7; CD34; activation antigens e.g. CD69 and IL- 2R.
  • CD8 CD16
  • CD4 CD3
  • selectins e.g. E-selectin
  • CD5 CD7
  • CD34 activation antigens
  • activation antigens e.g. CD69 and IL- 2R.
  • other receptor - ligand interactions can be used for targeting e.g. CD4 to target HIV gp 160 - expressing target cells.
  • antibody targeted DNA is preferred, particularly antibody targeted naked DNA, antibody targeted condensed DNA and especially antibody targeted liposomes.
  • liposomes which may be used include for example pH-sensitive liposomes where linkers cleaved at low pH may be used to link the antibody to the liposome.
  • Cationic liposomes which fuse with the cell membrane and deliver the recombinant chimeric receptor DNA according to the invention directly into the cytoplasm may also be used.
  • Liposomes for use in the invention may also have hydrophilic groups attached to their surface to increase their circulating half-life such as for example polyethylene glycol polymers. There are many examples in the art of suitable groups for attaching to liposomes or other carriers; see for example International Patent Specifications Nos.
  • the antibody or other targeting molecule may be linked to the DNA, condensed DNA or liposome using conventional readily available linking groups and reactive functional groups in the antibody e.g. thiols, or amines and the like, and in the DNA or DNA containing materials.
  • Non-targeted delivery systems may also be used and in these targeted expression of the DNA is advantageous.
  • Targeted expression of the DNA may be achieved for example by using T-cell specific promoter systems such as the zeta promoter and CD2 promoter and locus control region, and the perforin promoter.
  • a first and second separate DNA coding sequence may be present in the delivery system each of which codes for components i) to iv) and optionally v) in the same reading frame as described above but which differ from each other in that the cytoplasmic signalling component iv) is not the same, and always providing of course that at least one of the signalling components is a co-stimulatory signalling domain as described herein.
  • the two DNA coding sequences may each code for more than one signalling component providing that at least one component on the first DNA is different to any other signalling component on the second DNA.
  • the signalling components are advantageously selected to act cooperatively and the remaining components may be any of those previously described for the single DNA embodiment.
  • the binding component iv) coded for by the first DNA will preferably be the same as that coded for by the second DNA.
  • the binding component coded by the first DNA will be separated from the transmembrane component by a different spacer region to that coded by the second DNA.
  • the delivery system may be used ex vivo and in a further aspect the invention provides effector cells transfected with a DNA delivery system according to the invention.
  • the effector cells may be any of those previously described above which are suitable for ex vivo use and are preferably T-cells most preferably cytotoxic T-cells.
  • the DNA delivery system may take the form of a pharmaceutical composition. It may be a therapeutic or diagnostic composition and may take any suitable form suitable for administration. Preferably it will be in a form suitable for parenteral administration e.g. by injection or infusion, for example by bolus injection or continuous infusion. Where the composition is for injection or infusion, it may take the form of a suspension, solution or emulsion in an oily or aqueous vehicle and it may contain formulatory agents such as suspending, preservative, stabilising and/or dispersing agents. Alternatively, the composition may be in dry form, for reconstitution before use with an appropriate sterile liquid.
  • the formulation may contain, in addition to the active ingredient, additives such as: starch - e.g. potato, maize or wheat starch or cellulose - or starch derivatives such as microcrystalline cellulose; silica; various sugars such as lactose; magnesium carbonate and/or calcium phosphate. It is desirable that, if the formulation is for oral administration it will be well tolerated by the patient's digestive system. To this end, it may be desirable to include in the formulation mucus formers and resins. It may also be desirable to improve tolerance by formulating the compositions in a capsule which is insoluble in the gastric juices. It may also be preferable to include the composition in a controlled release formulation.
  • additives such as: starch - e.g. potato, maize or wheat starch or cellulose - or starch derivatives such as microcrystalline cellulose; silica; various sugars such as lactose; magnesium carbonate and/or calcium phosphate.
  • the DNA delivery system according to the invention is of use in medicine and the invention extends to a method of treatment of a human or animal subject, the method comprising administering to the subject an effective amount of a DNA delivery system described above.
  • the exact amount to be used will depend on the ages and condition of the patient, the nature of the disease or disorder and the route of administration, but may be determined using conventional means, for example by extrapolation of animal experiment derived data.
  • the number of transfected effector cells required may be established by ex vivo transfection and re-introduction into an animal model of a range of effector cell numbers.
  • the quantity of DNA required for in vivo use may be established in animals using a range of DNA concentrations.
  • the DNA delivery system according to the invention may be useful in the treatment of a number of diseases or disorders.
  • diseases or disorders may include those described under the general headings of infectious diseases, e.g. HIV infection; inflammatory disease/autoimmunity e.g. rheumatoid arthritis, osteoarthritis, inflammatory bowel disease; cancer; allergic/atopic diseases e.g. asthma, eczema; congenital e.g. cystic fibrosis, sickle cell anaemia; dermatologic, e.g. psoriasis; neurologic, e.g. multiple sclerosis; transplants e.g. organ transplant rejection, graft-versus-host disease; metabolic/idiopathic disease e.g. diabetes.
  • infectious diseases e.g. HIV infection
  • inflammatory disease/autoimmunity e.g. rheumatoid arthritis, osteoarthritis, inflammatory bowel disease
  • cancer allergic/atopic diseases e.g. asthma, e
  • DNA coding for a chimeric receptor as described herein also forms a feature of the invention, particularly for use in a delivery system described herein.
  • the DNA coding for chimeric receptors according to the invention may be assembled from known DNA sequences and expressed in effector cells using the procedures and approaches generally described herein and in our International Patent Specification No. WO 97/23613 and more specifically in the Examples and Figures herein and in WO 97/23613.
  • Figures 1-21 illustrate chimeric receptor constructs [a-f in each Figure] of the invention.
  • Each component of these chimeric receptor constructs is either PCR cloned or assembled by standard techniques (PCR protocols, Innis et al, 1990, Academic Press inc. ). Each component is flanked by a 2 to 4 amino acid linkage forming a restriction site to allow in frame sub-cloning into pBluescript SK+ (Statagene) in a cassette format similar to that described in Example 1 of our International Patent Specification No. WO 97/23613
  • the P67 scFv / h.CD28 / CD9 - FcR ⁇ chimeric receptor consists of a single chain Fv of the engineered human antibody P67.6 specific for human CD33 linked to an extracellular spacer consisting of human lgG1 hinge and part of the extracellular region of human CD28 linked via part of human CD9 to the intracellular domain of the ⁇ chain of human Fc ⁇ RI.
  • the single chain Fv consists of the leader sequence and variable component of the light chain of the engineered human antibody linked via a (Gly4Ser)5 linker to the variable component of the heavy chain of the engineered human antibody.
  • the extracellular spacer consists of residues 234 to 243 of human lgG1 hinge and residues 118 to 134 of human CD28. This is linked via residues 52 to 227 of human CD9 (Boucheix et al (1991 ) J. Biol. Chem. 266. 117-122) to residues 27 to 68 of the ⁇ chain of human Fc ⁇ RI (Kuster et al (1989) J. Biol. Chem. 255, 6448-6452).
  • a single chain Fv such as P67scFv as just described, or hCTMOIscFv as described in Example 1 of WO 97/23613 may be linked to an extracellular spacer, for example consisting of human lgG1 hinge and part of the extracellular region of human CD28 as just described, then linked to the various tansmembrane and intracellular components shown.
  • each co-stimulatory domain is shown as CD9 36-227, CD37 38-281 , etc.
  • the size of the particular CD28, zeta and FcR ⁇ component used is not shown, then the same or similarly sized components may be used as described above in the case of FcR ⁇ or as described as described in Example 1 of WO 97/
  • the full length chimeric receptor construct was sub-cloned from pBluescript into the expression vector pEE6hCMV.ne [Bebbington (1991), Methods 2, 136-145] on a Hind III to EcoR I restriction fragment.
  • Plasmids were linearised and transfected into Jurkat E6.1 cells (ECACC) by electroporation using a Bio-Rad Gene Pulser using two 1 second pulses of 1000V and 3 ⁇ F. Chimeric receptor expressing cell lines were selected in media containing the drug G418 (2 mg/ml) After approximately four weeks cells were analysed for their ability to express surface scFv and to produce IL-2.
  • Figure 22 shows clear surface expression of the P67scFV / h.CD28 / CD9 - FcR ⁇ chimeric receptor on transfected Jurkat cells as measured with fluorescein-conjugated human CD33.
  • Figure 23 shows antigen specific IL-2 production by Jurkat cells transfected with the P67scFV / h.CD28 / CD9 - FcR ⁇ chimeric receptor compared to untransfected Jurkat cells when stimulated with antigen positive target cells [HL60 and N.CD33 (the mouse myeloma NSO expressing human CD33)] as compared to no target cells or antigen negative cells [N.EE6 (the mouse myeloma NSO expressing a control plasmid)].
  • antigen positive target cells [HL60 and N.CD33 (the mouse myeloma NSO expressing human CD33)] as compared to no target cells or antigen negative cells [N.EE6 (the mouse myeloma NSO expressing
  • the figure shows that in the presence of the antigen (CD33) positive cells transfected Jurkat cells expressing the chimeric receptor were stimulated to produce IL-2. The same cells failed to produce IL-2 in the presence of cells not presenting the antigen. In each instance, non- transfected Jurkat control cells also failed to respond and produced no measurable quantities of IL-2.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un procédé d'activation de cellule dans lequel une cellule effectrice est transformée avec un ADN codant un récepteur chimère contenant deux ou plusieurs composants de signalisation cytoplasmiques différents. Au moins un des composants de signalisation cytoplasmiques est dérivé de tout ou d'une partie d'une protéine transmembranaire à tétra couverture, CD43, CD6, d'un mannose, IL-7, IL-12 ou d'un récepteur du complément, d'une protéine associée à l'intégrine, ou d'une chaîne η associée à un récepteur de cytokine. La cellule activée peut s'utiliser dans le domaine médical, par exemple dans le traitement de maladies telles que le cancer.
EP98930934A 1997-06-25 1998-06-24 Procede d'activation de cellule et reactifs a cet effet Withdrawn EP1002073A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9713473 1997-06-25
GBGB9713473.8A GB9713473D0 (en) 1997-06-25 1997-06-25 Biological products
PCT/GB1998/001842 WO1999000494A2 (fr) 1997-06-25 1998-06-24 Procede d'activation de cellule et reactifs a cet effet

Publications (1)

Publication Number Publication Date
EP1002073A2 true EP1002073A2 (fr) 2000-05-24

Family

ID=10814935

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98930934A Withdrawn EP1002073A2 (fr) 1997-06-25 1998-06-24 Procede d'activation de cellule et reactifs a cet effet

Country Status (5)

Country Link
EP (1) EP1002073A2 (fr)
JP (1) JP2002511757A (fr)
AU (1) AU8121098A (fr)
GB (1) GB9713473D0 (fr)
WO (1) WO1999000494A2 (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9809658D0 (en) * 1998-05-06 1998-07-01 Celltech Therapeutics Ltd Biological products
GB9908807D0 (en) * 1999-04-16 1999-06-09 Celltech Therapeutics Ltd Synthetic signalling molecules
GB9908816D0 (en) * 1999-04-16 1999-06-09 Celltech Therapeutics Ltd Biological product
GB9908814D0 (en) * 1999-04-16 1999-06-09 Celltech Therapeutics Ltd Process
GB9925848D0 (en) * 1999-11-01 1999-12-29 Celltech Therapeutics Ltd Biological products
AU2002314881A1 (en) * 2001-06-07 2002-12-23 Rigel Pharmaceuticals, Inc. Cd43:modulators of mast cell degranulation
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
WO2007056812A1 (fr) * 2005-11-16 2007-05-24 Apollo Life Sciences Limited Molecule et molecules chimeres de celle-ci
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
PL2958943T3 (pl) 2013-02-20 2020-04-30 The Trustees Of The University Of Pennsylvania Leczenie nowotworu złośliwego za pomocą humanizowanego chimerycznego receptora antygenowego anty-egfrviii
ES2814962T3 (es) 2013-02-20 2021-03-29 Novartis Ag Fijación eficaz como objetivo de la leucemia humana primaria utilizando células T modificadas con receptor de antígeno quimérico anti-CD123
ES3058841T3 (en) 2013-03-15 2026-03-13 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
CA2931684C (fr) 2013-12-19 2024-02-20 Novartis Ag Recepteurs antigeniques chimeriques de la mesotheline humaine et leurs utilisations
EP4420663A3 (fr) 2013-12-20 2024-10-30 Novartis AG Récepteur d'antigène chimère régulable
EP4303229A3 (fr) 2014-01-21 2024-04-17 Novartis AG Capacité améliorée de présentation de l'antigène de lymphocytes t de récepteur d'antigène chimérique (car) par l'introduction conjointe de molécules de stimulation conjointe
SI3888674T1 (sl) 2014-04-07 2024-08-30 Novartis Ag Zdravljenje raka z uporabo antigenskega himernega receptorja proti-CD19
KR20210014210A (ko) 2014-05-15 2021-02-08 내셔널 유니버시티 오브 싱가포르 변형된 천연 살해 세포 및 그의 용도
WO2016014553A1 (fr) 2014-07-21 2016-01-28 Novartis Ag Récepteurs d'antigènes chimères synthétisés par l'intermédiaire d'une sortase
SG10201913765YA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
US10174095B2 (en) 2014-07-21 2019-01-08 Novartis Ag Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
RU2020117196A (ru) 2014-08-19 2020-10-15 Новартис Аг Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей
JP6839074B2 (ja) 2014-09-17 2021-03-03 ノバルティス アーゲー 養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
CA2963935A1 (fr) 2014-10-08 2016-04-14 Novartis Ag Biomarqueurs predictifs de la reactivite therapeutique a une therapie par recepteurs antigeniques chimeres et leurs utilisations
IL253149B2 (en) 2014-12-29 2023-11-01 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2016115482A1 (fr) 2015-01-16 2016-07-21 Novartis Pharma Ag Promoteurs de phosphoglycérate kinase 1 (pgk) et procédés d'utilisation pour l'expression d'un récepteur antigénique chimérique
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
IL303972A (en) 2015-04-08 2023-08-01 Novartis Ag CD20 treatments, CD22 treatments and combined treatments with CD19 chimeric antigen receptor expressing cell
WO2016168595A1 (fr) 2015-04-17 2016-10-20 Barrett David Maxwell Procédés pour améliorer l'efficacité et l'expansion de cellules exprimant un récepteur antigénique chimérique
EP3286211A1 (fr) 2015-04-23 2018-02-28 Novartis AG Traitement du cancer à l'aide de protéine récepteur antigénique chimérique et un inhibiteur de protéine kinase
AU2016297014B2 (en) 2015-07-21 2021-06-17 Novartis Ag Methods for improving the efficacy and expansion of immune cells
US11667691B2 (en) 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
US11747346B2 (en) 2015-09-03 2023-09-05 Novartis Ag Biomarkers predictive of cytokine release syndrome
IL259576B (en) 2015-12-04 2022-09-01 Novartis Ag grna molecule containing tracr and crrna, pharmaceutical composition containing it and method for preparing cells for immunotherapy
US11413340B2 (en) 2015-12-22 2022-08-16 Novartis Ag Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
MY200337A (en) 2016-10-07 2023-12-20 Novartis Ag Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain
EP3574005B1 (fr) 2017-01-26 2021-12-15 Novartis AG Compositions de cd28 et procédés pour une thérapie à base de récepteur antigénique chimérique
CA3054621A1 (fr) 2017-03-22 2018-09-27 Novartis Ag Compositions et procedes d'immuno-oncologie
CA3056439A1 (fr) 2017-03-27 2018-10-04 National University Of Singapore Recepteurs chimeriques de nkg2d tronques et leurs utilisations dans une immunotherapie de cellules tueuses naturelles
US11999802B2 (en) 2017-10-18 2024-06-04 Novartis Ag Compositions and methods for selective protein degradation
CN112218651A (zh) 2018-01-08 2021-01-12 诺华公司 用于与嵌合抗原受体疗法组合的免疫增强rna
SG11202007156QA (en) 2018-02-09 2020-08-28 Nat Univ Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
SG11202008976YA (en) 2018-04-02 2020-10-29 Nat Univ Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
JP7438988B2 (ja) 2018-06-13 2024-02-27 ノバルティス アーゲー Ｂｃｍａキメラ抗原受容体及びその使用
US12486514B2 (en) 2018-08-29 2025-12-02 National University Of Singapore Method to specifically stimulate survival and expansion of genetically-modified immune cells
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
CN114761037A (zh) 2019-11-26 2022-07-15 诺华股份有限公司 结合bcma和cd19的嵌合抗原受体及其用途
IL292924A (en) 2019-11-26 2022-07-01 Novartis Ag Chimeric antigen receptors cd19 and cd22 and their uses
WO2023081878A2 (fr) * 2021-11-08 2023-05-11 Baylor College Of Medicine Cellules immunitaires modifiées et leurs procédés d'utilisation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712149A (en) * 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US6103521A (en) * 1995-02-06 2000-08-15 Cell Genesys, Inc. Multispecific chimeric receptors
GB9526131D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9900494A2 *

Also Published As

Publication number Publication date
WO1999000494A3 (fr) 1999-03-25
JP2002511757A (ja) 2002-04-16
AU8121098A (en) 1999-01-19
WO1999000494A2 (fr) 1999-01-07
GB9713473D0 (en) 1997-09-03

Similar Documents

Publication Publication Date Title
US20030060444A1 (en) Cell activation process and reagents therefor
EP1002073A2 (fr) Procede d'activation de cellule et reactifs a cet effet
AU768761B2 (en) Chimeric receptors
Mazinani et al. CAR-T cell potency: from structural elements to vector backbone components
AU729757B2 (en) Cell activation process and reagents therefor
CN110760007B (zh) Cd7-car-t细胞及其制备和应用
US7052906B1 (en) Synthetic transmembrane components
US5712149A (en) Chimeric receptor molecules for delivery of co-stimulatory signals
EP1226244B1 (fr) Polypeptides a motifs de signalisation primaire non naturelle
EP1289564B1 (fr) Fusions et conjugues de recepteurs de lymphocytes t et procedes d'utilisation correspondants
JP2022522654A (ja) Ｐｄ－１外部ドメインを担持するキメラサイトカイン受容体
US20060247191A1 (en) Chimeric cytoplasmic signalling molecules
JP2004511246A (ja) Ｃｄ１３７由来キメラ細胞質シグナリング分子
CA3002774A1 (fr) Recepteurs de cellules universels programmables et leurs procedes d'utilisation
WO2020108090A1 (fr) Lymphocytes t-car ayant cd19 scfv humanisé portant une mutation dans la région cdr1
WO2000063373A1 (fr) Methode destinee a modifier les proprietes d'une proteine associee a une membrane par substitution du domaine transmembranaire
WO2001032866A2 (fr) Recepteurs-adaptateurs
WO2001032867A1 (fr) Polypeptides possedant des motifs primaires de signalisation etendus

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000113

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20040723

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060411